Clinical Trials

Study Title:
Phase 3 Study of Loncastuximab Tesirine, an Anti-CD-19 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

For more information about the trial above please contact the study team:

Principal Investigator, Brian Hess, at

Study Coordinator, Sarah Britton, at, or please call +1 843-792-8856.

Trial opened at the following institutions: Medical University of South Carolina